Serum paraoxonase 1 (PON1) measurement: An update

BMC Veterinary Research

Volumn 10, Issue , 2014, Pages

  Ceron, Jose J ^a   Tecles, Fernando ^a   Tvarijonaviciute, Asta ^b  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

4 nitrophenyl acetate; Dihydrocoumarin; Paraoxon; Phenyl acetate; Serum; TBBL

Indexed keywords

ARYLDIALKYLPHOSPHATASE; INSECTICIDE; PARAOXON;

ANIMAL; BLOOD; GENETIC POLYMORPHISM; HUMAN; ORGANOPHOSPHATE POISONING; TOXICITY;

ANIMALS; ARYLDIALKYLPHOSPHATASE; HUMANS; INSECTICIDES; ORGANOPHOSPHATE POISONING; PARAOXON; POLYMORPHISM, GENETIC;

EID: 84899126686     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-10-74     Document Type: Review

References (80)

1. Martinelli N, Consoli L, Girelli D, Grison E, Corrocher R, Olivieri O. Paraoxonases: ancient substrate hunters and their evolving role in ischemic heart disease. Adv Clin Chem 2013, 59:65-100.
2. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991, 286:152-154. 10.1016/0014-5793(91)80962-3, 1650712.
3. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000, 43:33435-33442.
4. Costa LG, Vitalone A, Cole T, Furlong C. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005, 69:541-550. 10.1016/j.bcp.2004.08.027, 15670573.
5. Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta 2009, 410:1-12. 10.1016/j.cca.2009.09.025, 19799889.
6. Camps J, Marsillach J, Joven J. The paraoxonase: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009, 46:83-106. 10.1080/10408360802610878, 19255916.
7. Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact 2010, 187:355-361. 10.1016/j.cbi.2010.03.033, 3035622, 20338154.
8. James RW. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 2007, 44:1052-1059.
9. Novak F, Vavrova L, Kodydkova J, Novak F, Hynkova M, Zak A, Novakova O. Decreased paraoxonase activity in critically ill patients with sepsis. Clin Exp Med 2010, 10:21-25. 10.1007/s10238-009-0059-8, 19760042.
10. Mogarekar MR, Talekar SJ. Serum lactonase and arylesterase activities in alcoholic hepatitis and hepatitis B. Indian J Gastroenterol 2013, 32:307-310. 10.1007/s12664-013-0334-1, 23700138.
11. Miyamoto T, Takahashi Y, Oohashi T, Sato K, Oikawa S. Bovine paraoxonase 1 activities in serum and distribution in lipoproteins. J Vet Med Sci 2005, 67:243-248. 10.1292/jvms.67.243, 15805725.
12. Turk R, Juretić D, Geres D, Svetina A, Turk N, Flegar-Mestrić Z. Influence of oxidative stress and metabolic adaptation on PON1 activity and MDA level in transition dairy cows. Anim Reprod Sci 2008, 108:98-106. 10.1016/j.anireprosci.2007.07.012, 17850995.
13. Motta S, Letellier C, Ropert M, Motta C, Thiébault JJ. Protecting effect of vitamin E supplementation on submaximal exercise-induced oxidative stress in sedentary dogs as assessed by erythrocyte membrane fluidity and paraoxonase-1 activity. Vet J 2009, 181:288-295. 10.1016/j.tvjl.2008.03.013, 18479950.
14. Tvarijonaviciute A, Kocaturk M, Cansev M, Tecles F, Ceron JJ, Yilmaz Z. Serum butyrylcholinesterase and paraoxonase 1 in a canine model of endotoxemia: effects of choline administration. Res Vet Sci 2012, 93:668-674. 10.1016/j.rvsc.2011.09.010, 22000805.
15. Tvarijonaviciute A, Ceron JJ, Holden SL, Morris PJ, Biourge V, German AJ. Effects of weight loss in obese cats on biochemical analytes related to inflammation and glucose homeostasis. Domest Anim Endocrinol 2012, 42:129-141. 10.1016/j.domaniend.2011.10.003, 22177629.
16. Turk R, Habuš J, Flegar-Meštrić Z, Svetina A, Mojčec V, Perkov S, Belić M, Starešina V, Turk N. Serum platelet-activating factor acetylhydrolase and paraoxonase-1 activity in horses infected with Leptospira spp. Acta Trop 2011, 118:97-100. 10.1016/j.actatropica.2011.03.002, 21414286.
17. Costa LG, Cole TB, Vitalone A, Furlong CE. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 2005, 352:37-47. 10.1016/j.cccn.2004.09.019, 15653099.
18. Richter RJ, Jarvick GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 2009, 235:1-9. 10.1016/j.taap.2008.11.001, 3045428, 19071155.
19. Khersonsky O, Tawfik DS. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chem Bio Chem 2006, 7:49-53. 10.1002/cbic.200500334, 16329153.
20. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalia J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996, 14:334-336. 10.1038/ng1196-334, 8896566.
21. Teiber JF, Draganov DI, La Du B. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol 2003, 66:887-896. 10.1016/S0006-2952(03)00401-5, 12963475.
22. Mogarekar MR, Chawhan SS. The determination of Q192R polymorphism of paraoxonase 1 by using non-toxic substrate p-nitrophenyl acetate. Indian J Hum Genet 2013, 19:71-77. 10.4103/0971-6866.112897, 3722633, 23901196.
23. Browne RW, Koury ST, Marion S, Wilding G, Muti P, Trevisan M. Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay. Clin Chem 2007, 53:310-317.
24. Charlton-Menys V, Liu Y, Durrington P. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin Chem 2006, 52:453-457. 10.1373/clinchem.2005.063412, 16423902.
25. Liao F, Zhu X, Wang Y, Zhao Y, Zhu L, Zuo Y. Correlation of serum arylesterase activity on phenyl acetate estimated by the integrated method to common classical biochemical indexes of liver damage. J Zheijang University Sci B 2007, 8:237-241.
26. Dantoine T, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998, 9:2082-2088.
27. Keskin M, Dolar E, Dirican M, Kiyici M, Ylmaz Y, Gurel S, Nak SG, Erdinc S, Gulten M. Baseline and salt-stimulated paraoxonase and aryesterase activities in patients with chronic liver disease: relation to disease activity. Inter Med J 2009, 39:243-248.
28. Roest M, van Himbergen TM, Barendrecht AB, Peeters PH, van der Schouw YT, Voorbij HA. Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest 2007, 37:187-196. 10.1111/j.1365-2362.2007.01769.x, 17359486.
29. Smolen A, Eckerson H, Gan KN, Hailat N, La du B. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Met Disp 1991, 19:107-112.
30. Connelly PW, Maguire GF, Picardo CM, Teiber JF, Draganov D. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J Lipid Res 2008, 49:245-250. 10.1194/jlr.D700022-JLR200, 17906223.
31. Kujiraoka T, Oka T, Ishihara M, Egashira T, Fujioka T, Saito E, Saito S, Miller NE, Hattori H. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res 2000, 41:1358-1363.
32. Marsillach J, Aragonès G, Beltrán R, Caballeria J, Pedro-Botet J, Morcillo-Suárez C, Navarro A, Joven J, Camps J. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 2009, 42:91-98. 10.1016/j.clinbiochem.2008.09.120, 18977341.
33. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000, 28:1335-1342.
34. Huen K, Ritcher R, Furlong C, Eskenazi B, Holland N. Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta 2009, 402:67-74. 10.1016/j.cca.2008.12.019, 2683673, 19146843.
35. Ferré N, Camps J, Cabré M, Paul A, Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabol 2001, 50:997-1000.
36. Tomas M, Senti M, Garcia F, Vila J, Torrents A, Covas M, Marrugar J. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familal hypercholesterolemic patients. Art Thrombosis Vasc Biol 2000, 20:2113-2119.
37. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011, 81:337-344. 10.1016/j.bcp.2010.11.008, 3077125, 21093416.
38. Watson CE, Draganow DI, Billecke SS, Bisgaier CL, La Du BN. Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. Pharmacogen 2001, 11:123-124.
39. Augustinson KB, Olsson B. Genetic control of arylesterase in the pig. Hereditas 1961, 47:1-22.
40. Augustinson KB, Olsson B. Esterases in the milk and blood plasma of swine. Activities at different stages during the lactation and suckling periods and plasma arylesterase as a gene-controlled enzyme. Biochem J 1959, 71:484-492. 1196821, 13638254.
41. Augustinson KB. Arylesterases. J. Histochem Cytochem 1964, 12:744-747. 10.1177/12.10.744, 14221055.
42. Mackness MI, Arrol S, Durrington P. Substrate specificity of human serum paraoxonase. Biochem Soc Trans 1991, 19:304S.
43. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000, 10:767-779. 10.1097/00008571-200012000-00002, 11191881.
44. Loscalzo J. Paraoxonase and coronary heart disease risk. Language misleads, linkage misinforms, function clarifies. Circul Cardiov Gen 2008, 1:79-80.
45. Aldridge WN. Serum esterases II. An enzyme hydrolysing dietil p-nitrophenyl acetate (E600) and its identity with the A-esterase of mammaliam sera. Biochem J 1953, 53:117-124. 1198111, 13032042.
46. Main AR. The differentiation of the A-type esterases in sheep serum. Biochem J 1960, 75:188-195. 1204348, 14420012.
47. Augustinson KB, Olsson B. Esterases in the milk and blood plasma of swine. Substrate specificity and electrophoresis studies. Biochem J 1959, 71:477-484. 1196820, 13638253.
48. Tvarijonaviciute A, Tecles F, Caldin M, Tasca S, Ceron JJ. Validation of spectrophotometric assays for serum paraoxonase type-1 measurement in dogs. Am J Vet Res 2012, 73:34-41. 10.2460/ajvr.73.1.34, 22204286.
49. Bahar FG, Ohura K, Ogihara T, Imai T. Species differences of esterase expression and hydrolase activity in plasma. J Pharm Sci 2012, 101:10. 10.1002/jps.22756, 21922462.
50. Kotani K, Sakane N, Sano Y. Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women. J Clin Biochem Nutr 2009, 45:329-334. 10.3164/jcbn.09-26, 2771255, 19902024.
51. Farid AS, Honkawa K, Fath EM, Nonaka N, Horii Y. Serum paraoxonase-1 as biomarker for improved diagnosis of fatty liver in dairy cows. BMC Vet Res 2013, 9:73. 10.1186/1746-6148-9-73, 3637055, 23578174.
52. Khersonsky O, Tawfil DS. The histidine 115-histidone 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J Biol Chem 2006, 281:7649-7656. 10.1074/jbc.M512594200, 16407305.
53. Parra S, Marsillach J, Aragones G, Rull A, Beltran R, Alonso C, Joven J, Camps J. Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV- infected patients. Lipids Health Dis 2010, 9:32-36. 10.1186/1476-511X-9-32, 2852375, 20334696.
54. Ferré N, Feliu A, García-Heredia A, Marsillach J, París N, Zaragoza-Jordana M, Mackness B, Mackness M, Escribano J, Closa-Monasterolo R, Joven J, Camps J. Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. Clin Biochem 2013, in press.
55. Furlong CE, Ritcher RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/aryleserase in hydrolysis of the insecticide metabolitos chlorpyrifos oxon and paraoxon. Am J Hum Gen 1988, 43:230-238.
56. Mu X, Yu N, Wang C, Zou X, Albulimite A, Xia Z. Evaluation of a new substrate for measurement of serum PON arylesterase activity. Talanta 2012, 15:711-716.
57. Main AR. The purification of the enzyme hydrolysing diethyl p-nitrophenil phosphate (paraoxon) in sheep serum. Biochem J 1960, 74:10-20. 1204042, 14420013.
58. Golmanesh L, Mehrani H, Tabei M. Simple procedures for purification and stabilization of human serum paraoxonase-1. J Biochem Biophys Methods 2008, 70:1037-1042. 10.1016/j.jbbm.2007.09.003, 17928061.
59. Brushia RJ, Forte TM, Oda MN, LaDu NB, Bielicki JK. Baculovirus-mediated expression and purification of human serum paraoxonase 1A. J Lipid Res 2001, 42:951-958.
60. Khersonsky O, Tawfil DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochem 2005, 44:6371-6382.
61. Furlong CE, Ritcher RJ, Seidel S, Costa L, Motulsky A. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlropyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem 1989, 180:242-247. 10.1016/0003-2697(89)90424-7, 2479288.
62. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Europ J Clin Chem Clinical Biochem 1992, 30:391-395.
63. Kuo CL, La Du BN. Comparsion of purified human and rabbit serum paraoxonases. Drug Metab Dispos 1995, 23:935-944.
64. Eckerson HW, Wyte CM, La Du B. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983, 35:1126-1138. 1685985, 6316781.
65. Junge W, Klees H. 1,2-Arylesterase. Methods Enzym Anal 1984, 4:8-14.
66. Mackness M, Mackness B. Effect of dilution on high-density lipoprotein associated paraoxonase-1 activity. Clin Biochem 2011, 44:1270-1271. 10.1016/j.clinbiochem.2011.08.002, 21854764.
67. Nakanishi M, Takanami Y, Maruyama T, Murata M, Motohashi Y, Nakano S, Uchida K, Maruyama C, Kyotani S, Tsushima M. The ration of serum paraoxonase /arylesterase activity using an improved assay for arylesterase activity to discriminate PON1R192 from PO1Q192. J Ather Thromb 2003, 10:337-342.
68. Erdos EG, Boggs LE. Hydrolysis of paraoxon in mammalian blood. Nature 1961, 190:716. 10.1038/190716a0, 13697084.
69. Mackness I. Why plasma should not be used to study paraoxonase?. Atherosclerosis 1998, 136:195-196. 10.1016/S0021-9150(97)00197-4, 9544747.
70. Aldridge WN. Enzymes Hydrolysing Organophosphorous Compounds 1989, 1. Chichester: Ellis Horwood, Reiner E, Aldridge WN, Hoskin FCG.
71. Ferré N, Camps J, Marsillach J, Mackness B, Mackness M, Coll B, Tous M, Joven J. Comparison of paraoxonase 1 measurements in serum and in lithium-heparin anticoagulated plasma samples. Clin Chem 2005, 51:922-923. 10.1373/clinchem.2005.048231, 15855675.
72. Cerón JJ, Martínez-Subiela S, Hennemann C, Tecles F. The effects of different anticoagulants on routine canine plasma biochemistry. Vet J 2004, 167:294-301. 10.1016/j.tvjl.2003.09.009, 15080879.
73. Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005, 70:1673-1684. 10.1016/j.bcp.2005.09.002, 16213467.
74. Anderson J, Byrne T, Woelfel KJ, Meany JE, Spyridis GT, Pocker Y. The hydrolysis of p-nitrophenyl acetate: a versatile reaction to study enzyme kinetics. J Chem Educ 1994, 71:715-718.
75. Sterling D, Reithmeier RA, Casey JR. Carbonic anhydrase: in the driver's seat for bicarbonate transport. JOP 2001, 2:165-170.
76. Unal E, Uzun H, Kusaslan R, Dogan M, Genc H, Gunes P, Titiz I. Serum paraoxonase (a high-density lipoprotein-associated lipophilic antioxidant) activity and lipid profile in experimental acute pancreatitis. Pancreas 2005, 31:84-87. 10.1097/01.mpa.0000168227.74203.e4, 15968253.
77. Franco-Pons N, Marsillach J, Joven J, Camps J, Closa D. Serum paraoxonase undergoes inhibition and proteolysis during experimental acute pancreatitis. J Gast Sur 2008, 12:891-899.
78. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986, 32:671-673.
79. Chapuis N, Brühlmann C, Reist M, Carrupt PA, Mayer JM, Testa B. The esterase-like activity of serum albumin may be due to cholinesterase contamination. Pharm Res 2001, 18:1435-1439. 10.1023/A:1012204906502, 11697469.
80. Koitka M, Hochel J, Gieschen H, Borchert H. Improving the ex vivo stability of drug ester compounds in rat and dog serum: inhibition of the specific esterases and implications on their identity. J Pharm Biomed Anal 2010, 51:664-678. 10.1016/j.jpba.2009.09.023, 19850433.